About akronbiotech

Akron Biotech is an leading biotechnology company focused on discovery, development and manufacturing of advanced tools for regenerative medicine.

Driving Innovation & Lowering Cost of Goods through Improved Customer Management

At Akron, our Customer Relationship Management (CRM) system is more than just a database; it’s an adaptive framework that informs our developments and iterates based on our clients’ needs, just like our Quality Management System (QMS). The ideal CRM process focuses on the interactions between a business and its customers, with the principal goals of

Aseptic processing to maintain the integrity of ancillary materials for cell therapy manufacturing

Aseptic processing is one of the most critical steps in the production of biopharmaceuticals. It is uniquely challenging in its requirements for personnel and facilities. Avoiding contamination requires careful planning, effective personnel training, attention to detail on the part of technicians, and specialized facilities and equipment. These activities, skills, and facility features are necessary to

Advancements in biomedical engineering: developing hydrogels for tissue regeneration and drug delivery

Hydrogels are a 3-D network of highly absorbent polymers that have been investigated since the late 20th century for various biomedical applications, including drug delivery, wound healing, and tissue engineering. Their highly absorbent nature gives them a flexibility similar to natural tissues and allows oxygen, nutrients, proteins, and other biomolecules to readily enter and nourish

DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro

Dimethyl sulfoxide (DMSO) is an organic solvent that is widely used as cryoprotectant for freezing cells and tissues. Clinically, DMSO is considered a potent anti-inflammatory, nerve blocker (analgesic), diuretic, vasodilator and muscle relaxer. In cells, DMSO is used to induce differentiation, as a free radical scavenger, and most notably, to prevent ice formation during cryopreservation.

Akron Joins Leading Companies and Research Institutions at the ARMI | BioFabUSA Spring Summit to Accelerate Innovation in Tissue Engineering

Akron Biotech recently participated in the ARMI | BioFabUSA Spring Summit in Manchester, NH, joining several leading research institutions and companies to continue charting a path forward for the tissue engineering industry. If we think about innovation as a process of bringing old ideas together to make new things, then ARMI is uniquely suited to

Human-Derived Plasma Ancillary Materials for Cell Therapies: What Virus Inactivation Methods Should You Consider?

Human plasma is defined as “clear, straw colored, complex liquid that is 7% protein, 91% water, and 0.9% mineral salts” and can be derived from Source or Recovered Plasma. Today, human plasma is used to produce several ancillary materials such as Human AB Serum, Human Fibronectin, Human Serum Albumin (HSA), and Human Vitronectin. These materials

Trifunctional natural killer cell engagers show potential for solid tumor cancer therapies

Many cancer therapies that have emerged in the past decade have been developed to increase anti-tumor immunity. Specifically, these therapies promote innate and adaptive immune responses and equip the body’s own immune system to work as a weapon against tumors. Currently, most approaches have focused on enhancing T cell responses. One such approach targets inhibitory

Manufacturing Scale Up

The problems that arise when scaling up from small research batches to pilot-scale production to large-scale manufacturing aren’t always what you might expect them to be. While the concentration of the components in the formulation may not change, plenty of subtle idiosyncrasies noticed in the research phase can become huge hurdles on the commercial end

Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium

Cardiovascular disease is the leading cause of death in the world. This field has been the focus of several novel stem/progenitor cell-based therapies. These therapies have shown promising results in human clinical trials. Studies have demonstrated that cardiac progenitor cells (CPC; c-kit+/Lin−) and cardiomyocyte-derived cells (CDCs) from human neonatal cardiac tissue can reduce heart scar